September 20th 2020
Neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide demonstrated significant benefit in the treatment of patients with HR+/HER2- breast cancer.
The addition of neoadjuvant atezolizumab to nab-paclitaxel plus doxorubicin and cyclophosphamide significantly improved pathologic complete responses in patients with stage 2 or stage 3 triple-negative breast cancer, compared with placebo plus chemotherapy.
The addition of tamoxifen to abemaciclib resulted in an improvement in overall survival compared with abemaciclib monotherapy in in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, with benefit observed across all patient subgroups.
September 19th 2020
Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.
Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.
Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.
September 18th 2020
The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.
September 16th 2020
A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.
September 11th 2020
Heather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.
